Literature DB >> 29275463

Regulation of CTL Infiltration Within the Tumor Microenvironment.

Sarah E Church1,2,3, Jérôme Galon4,5,6.   

Abstract

The tumor microenvironment consists of a complex milieu of cells and factors that maintain equilibrium between tumor progression and destruction. Characterization of the immune contexture in primary tumors has consistently shown that T lymphocytes are an integral predictor of improved clinical outcome. This is notably true in colorectal carcinoma where high densities of cytotoxic or memory T lymphocytes in the invasive margin and the center of the primary tumor predict better patient survival, a measure termed Immunoscore. Since a high Immunoscore and pre-existing adaptive immune response are significantly correlated with improved clinical outcome, it is essential to understand the mechanisms underlying functional T lymphocyte infiltration into the tumor. The ability of cytolytic and memory T lymphocytes to migrate into tumors is regulated by multiple strategies including T lymphocyte help, homing factors, cytokines, tumor genotype, angiogenesis, lymphangiogenesis, and neurological signals. This chapter will discuss the predominant factors that mediate T-lymphocyte infiltration into tumors and how analysis of these biomarkers determine patients' disease-related survival and predicts response to cancer therapy.

Entities:  

Keywords:  Biomarkers; Chemokines; Colorectal cancer; Immunology; Immunoscore; Immunotherapy; Memory T lymphocytes; T-lymphocyte trafficking; Tumor microenvironment

Mesh:

Year:  2017        PMID: 29275463     DOI: 10.1007/978-3-319-67577-0_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

2.  Identification of an immune-related gene pair signature in breast cancer.

Authors:  Yue Zhan; Xin Guan; Yu Zhang; Zhenhua Zhu; Aiping Shi; Zhimin Fan
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

Review 3.  Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Authors:  Saraswoti Khadge; John Graham Sharp; Timothy R McGuire; Geoffrey M Thiele; Paul Black; Concetta DiRusso; Leah Cook; Lynell W Klassen; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2018-11-14       Impact factor: 4.932

4.  Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.

Authors:  Jun Zhang; Lanfen An; Xing Zhou; Rui Shi; Hongbo Wang
Journal:  Ann Transl Med       Date:  2021-04

5.  Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs.

Authors:  Dafni Chondronasiou; Tracy-Jane T H D Eisden; Anita G M Stam; Qiana L Matthews; Mert Icyuz; Erik Hooijberg; Igor Dmitriev; David T Curiel; Tanja D de Gruijl; Rieneke van de Ven
Journal:  Vaccines (Basel)       Date:  2018-07-18

Review 6.  Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

Authors:  Manja Idorn; Per Thor Straten
Journal:  Cells       Date:  2018-08-17       Impact factor: 6.600

7.  Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Authors:  Alessandro Ottaiano; Stefania Scala; Nicola Normanno; Maria Napolitano; Monica Capozzi; Anna Maria Rachiglio; Cristin Roma; Anna Maria Trotta; Crescenzo D'Alterio; Luigi Portella; Carmela Romano; Antonino Cassata; Rossana Casaretti; Lucrezia Silvestro; Anna Nappi; Salvatore Tafuto; Antonio Avallone; Alfonso De Stefano; Mario Tamburini; Carmine Picone; Antonella Petrillo; Francesco Izzo; Raffaele Palaia; Vittorio Albino; Alfonso Amore; Andrea Belli; Ugo Pace; Massimiliano Di Marzo; Paolo Chiodini; Gerardo Botti; Gianfranco De Feo; Paolo Delrio; Guglielmo Nasti
Journal:  BMC Cancer       Date:  2019-09-09       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.